EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.

Inclusion Criteria:

• 18-100 years old
• Biologically born female
• Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
• No cancer diagnosis (Arm 2-health control)

Exclusion Criteria:

• less than 18 years of age
• Biologically born male
• Incarcerated at the time of participation

Biologically born females

Female adult subjects who have EGFR positive lung cancer

The demographic variables of age, race and gender will be shared with our external collaborator at Louisiana State University, Dept of Chemical Engineering in order to draw broad conclusions about the sequencing data and to use these general categories for presentation and publication. Data will be de-identified upon sharing.

The data will be available and shared with collaborators upon completion of gene sequencing analysis of the final subject and remain available until IRB closure.

Only de-identified data will be shared with collaborators for the purpose of drawing conclusions and publication. Data will be sharing through a secure FileS system which is a HIPAA compliant platform offered by LSUHSC which limits access to only those for which the data is sent and does so in a secure manner.